Please login to the form below

Not currently logged in
Email:
Password:

Pegasus joins Ashfield Healthcare Communications

Acquired by UDG Healthcare in “strategically important” £16.8m deal
Pegasus joins Ashfield Healthcare Communications

From left: Simon Hackett, Lisa Bradley, Viv Adshead and David Moore

UK healthcare consultancy Pegasus has been bought by UDG Healthcare in a deal valued at up to £16.8m.

Pegasus becomes part of Ashfield Healthcare Communications, a subsidiary of UDG Healthcare's Ashfield Commercial and Medical Services Division, and will be under the leadership of its director David Moore.

Moore said that the acquisition of the healthcare consultancy is “strategically important” for the outsourced services provider.

“It strengthens our existing communications offering and broadens our capabilities in patient and consumer communications programmes, as well as corporate reputation and crisis management for our growing client base,” he added.

Pegasus is one of the UK's largest consumer healthcare-focused PR firms, with a team of 100 employees based in Brighton. Current clients include Daiichi Sankyo, Denplan, DuPont, Lloyds Pharmacy and Novo Nordisk.

Deputy managing director Simon Hackett becomes managing director, while Pegasus' founder Lisa Bradley will become the agency's chairman, taking over from Tim Adams who is departing.

Bradley commented: “Joining Ashfield will increase the breadth and depth of services we offer to our clients and will provide staff with the opportunity to acquire new skills.

“We know they are the right cultural fit for our agency and they share our passion for delivering innovative campaigns across healthcare.”

Article by
Rebecca Clifford

24th May 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics